Mesenchymal Stem Cells for Liver Regeneration in Liver Failure: From Experimental Models to Clinical Trials
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The liver centralizes the systemic metabolism and thus controls and modulates the functions of the central and peripheral nervous systems, the immune system, and the endocrine system. In addition, the liver intervenes between the splanchnic and systemic venous circulation, determining an abdominal portal circulatory system. The liver displays a powerful regenerative potential that rebuilds the parenchyma after an injury. This regenerative mission is mainly carried out by resident liver cells. However, in many cases this regenerative capacity is insufficient and organ failure occurs. In normal livers, if the size of the liver is at least 30% of the original volume, hepatectomy can be performed safely. In cirrhotic livers, the threshold is 50% based on current practice and available data. Typically, portal vein embolization of the part of the liver that is going to be resected is employed to allow liver regeneration in two-stage liver resection after portal vein occlusion (PVO). However, hepatic resection often cannot be performed due to advanced disease progression or because it is not indicated in patients with cirrhosis. In such cases, liver transplantation is the only treatment possibility, and the need for transplantation is the common outcome of progressive liver disease. It is the only effective treatment and has high survival rates of 83% after the first year. However, donated organs are becoming less available, and mortality and the waiting lists have increased, leading to the initiation of living donor liver transplantations. This type of transplant has overall complications of 38%. In order to improve the treatment of hepatic injury, much research has been devoted to stem cells, in particular mesenchymal stem cells (MSCs), to promote liver regeneration. In this review, we will focus on the advances made using MSCs in animal models, human patients, ongoing clinical trials, and new strategies using 3D organoids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Uygun, B. E., Soto-Gutierrez, A., Yagi, H., Izamis, M.-L., Guzzardi, M. A., Shulman, C., Milwid, J., Kobayashi, N., Tilles, A., Berthiaume, F., et al. (2010) · Nature Medicine · doi:10.1038/nm.2170 · Cited by 1,370
Long-Term Expansion of Functional Mouse and Human Hepatocytes as 3D Organoids
Hu, H., Gehart, H., Artegiani, B., LÖpez-Iglesias, C., Dekkers, F., Basak, O., van Es, J., Chuva de Sousa Lopes, S. M., Begthel, H., Korving, J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.013 · Cited by 837
Origin of myofibroblasts in the fibrotic liver in mice
Iwaisako, K., Jiang, C., Zhang, M., Cong, M., Moore-Morris, T. J., Park, T. J., Liu, X., Xu, J., Wang, P., Paik, Y.-H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400062111 · Cited by 535 · cited 1×
“In rats with obstructive cholestasis, portal fibroblasts are the first responders to liver injury [70, 71]; they proliferate and differentiate into myofibroblasts [72], which regulate cholangiocyte proliferation and interact, along with nonparenchymal cells, with fibrogenic stellate cells in order to stimulate their f…”
Differentiation of human adipose stromal cells into hepatic lineage in vitro and in vivo
Seo, M. J., Suh, S. Y., Bae, Y. C., & Jung, J. S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.12.158 · Cited by 530
Kharaziha, P., Hellström, P. M., Noorinayer, B., Farzaneh, F., Aghajani, K., Jafari, F., Telkabadi, M., Atashi, A., Honardoost, M., Zali, M. R., et al. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832a1f6c · Cited by 492 · cited 5×
“[46] also reported improved liver function in patients with cirrhosis who were injected with autologous MSCs via the portal vein.”
InfluentialHybrid Periportal Hepatocytes Regenerate the Injured Liver without Giving Rise to Cancer
Font-Burgada, J., Shalapour, S., Ramaswamy, S., Hsueh, B., Rossell, D., Umemura, A., Taniguchi, K., Nakagawa, H., Valasek, M. A., Ye, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.026 · Cited by 486
Kuo, T. K., Hung, S., Chuang, C., Chen, C., Shih, Y. V., Fang, S. Y., Yang, V. W., & Lee, O. K. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.015 · Cited by 466
Ductular reaction in liver diseases: pathological mechanisms and translational significances
Sato, K., Marzioni, M., Meng, F., Francis, H., Glaser, S., & Alpini, G. (2019) · Hepatology · doi:10.1002/hep.30150 · Cited by 423 · cited 3×
“In this sense, hepatocytes can transdifferentiate into cholangiocytes if there is severe biliary damage and cholangiocytes can transdifferentiate into hepatocytes in certain conditions of severe hepatocyte damage [36].”
Zhang, Z., Lin, H., Shi, M., Xu, R., Fu, J., Lv, J., Chen, L., Lv, S., Li, Y., Yu, S., et al. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07024.x · Cited by 372 · cited 1×
“[93] 46 UC-MSCs 0 5 × 106/kg Peripheral vein Decompensated liver cirrhosis”
Noël, D., Caton, D., Roche, S., Bony, C., Lehmann, S., Casteilla, L., Jorgensen, C., & Cousin, B. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.12.022 · Cited by 343
Suk, K. T., Yoon, J., Kim, M. Y., Kim, C. W., Kim, J. K., Park, H., Hwang, S. G., Kim, D. J., Lee, B. S., Lee, S. H., et al. (2016) · Hepatology · doi:10.1002/hep.28693 · Cited by 303 · cited 2×
“[89] is a phase 2 clinical trial with 55 patients with alcoholic cirrhosis.”
Higashiyama, R., Inagaki, Y., Hong, Y. Y., Kushida, M., Nakao, S., Niioka, M., Watanabe, T., Okano, H., Matsuzaki, Y., Shiota, G., et al. (2007) · Hepatology · doi:10.1002/hep.21477 · Cited by 261
Wang, Y., Wang, H., Deng, P., Chen, W., Guo, Y., Tao, T., & Qin, J. (2018) · Lab on a Chip · doi:10.1039/c8lc00869h · Cited by 222
Spee, B., Carpino, G., Schotanus, B. A., Katoonizadeh, A., Borght, S. V., Gaudio, E., & Roskams, T. (2010) · Gut · doi:10.1136/gut.2009.188367 · Cited by 208 · cited 1×
“In situations of hepatocyte injury (NAFLD, nonalcoholic steatohepatitis, cirrhosis, acute hepatitis, or cholangiopathies), an intermediate phenotype between stem and mature hepatocytes, so-called intermediate hepatocytes, is induced [20, 21].”
Tissue specific synthetic ECM hydrogels for 3-D in vitro maintenance of hepatocyte function
Skardal, A., Smith, L., Bharadwaj, S., Atala, A., Soker, S., & Zhang, Y. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.03.034 · Cited by 183
Amer, M.-E. M., El-Sayed, S. Z., El-Kheir, W. A., Gabr, H., Gomaa, A. A., El-Noomani, N., & Hegazy, M. (2011) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3283488b00 · Cited by 180 · cited 6×
“In another study, the authors reported that MSCs that were predifferentiated into hepatocyte-like cells were more efficient for liver fibrosis prevention [83].”
InfluentialEl-Ansary, M., Abdel-Aziz, I., Mogawer, S., Abdel-Hamid, S., Hammam, O., Teaema, S., & Wahdan, M. (2012) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9322-y · Cited by 179 · cited 2×
“Intraportal infusion appeared to be more efficient than via the peripheral route [83], and differentiation toward hepatocytes prior to infusion appeared not to increase MSC curative potential [90].”
Understanding Liver Regeneration
Gilgenkrantz, H., & Collin de l'Hortet, A. (2018) · The American Journal of Pathology · doi:10.1016/j.ajpath.2018.03.008 · Cited by 171 · cited 2×
“Depending on the amount of hepatic parenchyma removed, such as 30%, 60%, and 8090%, regeneration is mainly by hypertrophy, hyperplasia, or dedifferentiation in progenitor cells, respectively [13].”
Watanabe, Y., Tsuchiya, A., Seino, S., Kawata, Y., Kojima, Y., Ikarashi, S., Starkey Lewis, P. J., Lu, W.-Y., Kikuta, J., Kawai, H., et al. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0105 · Cited by 155
Mfsd2a+ hepatocytes repopulate the liver during injury and regeneration
Pu, W., Zhang, H., Huang, X., Tian, X., He, L., Wang, Y., Zhang, L., Liu, Q., Li, Y., Li, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms13369 · Cited by 136 · cited 1×
“In addition, both subpopulations of hepatocytes can repopulate each other in situations of chronic toxic injuries or after hepatectomies [15].”
Hepatic Fibrosis, Stellate Cells, and Portal Hypertension
Rockey, D. C. (2006) · Clinics in Liver Disease · doi:10.1016/j.cld.2006.08.017 · Cited by 112 · cited 1×
“This condition is hepatic cirrhosis in its final stages of evolution [3].”
Amin, M. A., Sabry, D., Rashed, L. A., Aref, W. M., el‐Ghobary, M. A., Farhan, M. S., Fouad, H. A., & Youssef, Y. A. (2013) · Clinical Transplantation · doi:10.1111/ctr.12179 · Cited by 88
Cited by
Psaraki, A., Ntari, L., Karakostas, C., Korrou‐Karava, D., & Roubelakis, M. G. (2022) · Hepatology · doi:10.1002/hep.32129 · Cited by 145
Mesenchymal stem cell therapy for liver fibrosis/cirrhosis
Cao, Y., Ji, C., & Lu, L. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.119 · Cited by 99
“liver fibrosis in several basic and clinical studies (5).”
BackgroundMazhari, S., Gitiara, A., Baghaei, K., Hatami, B., Rad, R. E., Asadirad, A., Joharchi, K., Tokhanbigli, S., Hashemi, S. M., Łos, M. J., et al. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173263 · Cited by 22
Li, Z., Zhou, X., Han, L., Shi, M., Xiao, H., Lin, M., & Chi, X. (2023) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-022-05528-1 · Cited by 18
Wang, Z., Jiang, T., Aji, T., Aimulajiang, K., Liu, Y., Lv, G., & Wen, H. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110227 · Cited by 18
Metadata
- Authors
- de Miguel, M. P., Prieto, I., Moratilla, A., Arias, J., & Aller, M. A.
- Venue
- Stem Cells International
- Publisher
- Wiley
- Published
- 2019-05-02
- Volume
- 2019
- Pages
- 1-12
- ISSN
- 1687-966X (ISSN-L)
- 1687-9678
- OpenAlex
- W2943369225
- Cited by
- 66
- References
- 22
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.